Algert Global LLC Takes Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Algert Global LLC purchased a new position in Gilead Sciences, Inc. (NASDAQ:GILD) in the fourth quarter, Holdings Channel reports. The fund purchased 34,791 shares of the biopharmaceutical company’s stock, valued at approximately $3,214,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of GILD. HHM Wealth Advisors LLC grew its position in shares of Gilead Sciences by 118.5% in the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 154 shares in the last quarter. YANKCOM Partnership acquired a new position in Gilead Sciences in the fourth quarter worth $28,000. Decker Retirement Planning Inc. bought a new stake in Gilead Sciences during the fourth quarter valued at $29,000. Crews Bank & Trust bought a new position in shares of Gilead Sciences in the 4th quarter worth about $31,000. Finally, Stephens Consulting LLC boosted its holdings in shares of Gilead Sciences by 325.0% in the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 260 shares during the period. 83.67% of the stock is owned by institutional investors.

Insider Buying and Selling at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $104.09, for a total transaction of $260,225.00. Following the completion of the sale, the chief financial officer now directly owns 169,061 shares of the company’s stock, valued at $17,597,559.49. This trade represents a 1.46 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In the last quarter, insiders have sold 160,605 shares of company stock worth $16,718,136. 0.27% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. JPMorgan Chase & Co. increased their price objective on shares of Gilead Sciences from $120.00 to $130.00 and gave the stock an “overweight” rating in a research note on Thursday, March 27th. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a report on Friday, April 25th. Piper Sandler lifted their target price on Gilead Sciences from $105.00 to $110.00 and gave the company an “overweight” rating in a research note on Wednesday, February 12th. Morgan Stanley raised their target price on shares of Gilead Sciences from $130.00 to $135.00 and gave the company an “overweight” rating in a research note on Friday, April 25th. Finally, Cantor Fitzgerald started coverage on shares of Gilead Sciences in a research note on Tuesday, April 22nd. They issued an “overweight” rating and a $125.00 price target for the company. Nine investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $110.55.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD opened at $98.90 on Thursday. The company has a market cap of $123.15 billion, a P/E ratio of 267.30, a price-to-earnings-growth ratio of 0.71 and a beta of 0.26. The company’s fifty day moving average is $107.95 and its two-hundred day moving average is $99.09. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $119.96.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.77 by $0.04. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The firm had revenue of $6.67 billion during the quarter, compared to the consensus estimate of $6.77 billion. During the same period in the prior year, the business earned ($1.32) EPS. The business’s revenue for the quarter was down .3% on a year-over-year basis. Equities analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 27th. Investors of record on Friday, June 13th will be given a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 3.20%. The ex-dividend date is Friday, June 13th. Gilead Sciences’s payout ratio is presently 66.53%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.